Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study

•In this population-based study that patients with MB, age-adjusted incidence rates remained relatively stable between 1975 and 2019.•Female incidence was stabilizing over time, while male incidence was increasing, with an APC of 0.35.This study evaluated independent prognostic factors associated wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical neuroscience 2024-08, Vol.126, p.154-161
Hauptverfasser: He, Dongjie, Yang, Yahui, Wu, Peiwen, Zhu, Siying, Chang, Hao, Zhang, Chao, Shao, Qiuju, Yu, Zongyan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 161
container_issue
container_start_page 154
container_title Journal of clinical neuroscience
container_volume 126
creator He, Dongjie
Yang, Yahui
Wu, Peiwen
Zhu, Siying
Chang, Hao
Zhang, Chao
Shao, Qiuju
Yu, Zongyan
description •In this population-based study that patients with MB, age-adjusted incidence rates remained relatively stable between 1975 and 2019.•Female incidence was stabilizing over time, while male incidence was increasing, with an APC of 0.35.This study evaluated independent prognostic factors associated with survival in patients with MB.•Patients with MB in the high-risk group may benefit from chemotherapy. Medulloblastoma (MB) is a primary brain malignancy. However, updated epidemiological data and long-term outcomes are lacking.The clinical and epidemiological datasets of patients with MB in the current study were obtained from the Surveillance, Epidemiology, and End Results (SEER) databases. Joinpoint regression models were used to assess the rate of changes in the incidence, prevalence, and treatment trends in patients with MB. Cox hazard and competition risk model analyses were used to assess overall survival (OS) and cancer-specific survival (CSS).The age-adjusted incidence of MB remained relatively stable at 0.15 per 100,000 individuals in 2019. The annual percentage change (APC) of females remained stable, whereas that of males increased over time. The 20-year limited-duration prevalence of patients with MB increased significantly from 0.00016 % in 1999 to 0.00203 % in 2018. Patients aged 5–19 years accounted for 46.7 % of all age groups, and the trend for the three treatments was increased. Average annual percentage change (AAPC) for the chemotherapy group was increased in patients aged 20 + years MB [AAPC = 2.66 (95 % CI 0.93–6.31)]. Multivariate analysis revealed that OS and CSS varied significantly according to age, year of diagnosis, histology, stage, surgery, and radiotherapy. Subgroup analysis showed that chemotherapy was associated with a favorable prognosis in high-risk groups.The incidence of MB remained relatively stable, and its prevalence increased significantly. This current population-based study further identified the prognostic factors in patients with MB. Moreover, the use of chemotherapy was associated with better survival in high-risk groups.
doi_str_mv 10.1016/j.jocn.2024.06.011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3070838031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0967586824002492</els_id><sourcerecordid>3070838031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-da49815a7eb2996a23f6490a8ab5d2f50cbe17d59827fc8cf83c684b538590cb3</originalsourceid><addsrcrecordid>eNp9kctu3CAUhlHUKJmmfYEuKpbd2OViMK66iaL0IkXKpl0jDMctI2xcwBPNO_Shy2jSLrsC6XznF3w_Qm8oaSmh8v2-3Ue7tIywriWyJZReoB0VnDVMCv4C7cgg-0Yoqa7Ry5z3hJCh4-QKXXM1VFrwHfp9v3oHs48h_vDWBFwSLC5jszg8GVtiqveco_WmgMNPvvzEeUsHf6isX_Bqioel5PNkBreFEMdgcomz-YBvcSeaI5iE17huocJxaUaTa1SCkmJewRZ_AJzL5o6v0OVkQobXz-cN-v7p_tvdl-bh8fPXu9uHxjLel8aZblBUmB5GNgzSMD7JbiBGmVE4NgliR6C9E4Ni_WSVnRS3UnWj4EoMdchv0Ltz7prirw1y0bPPFkIwC8Qta056orginFaUnVFbH5sTTHpNfjbpqCnRpxb0Xp9a0KcWNJG6eq1Lb5_zt7Eq-bfyV3sFPp4BqL88eEg626rRgvOpCtEu-v_l_wE5SJws</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070838031</pqid></control><display><type>article</type><title>Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study</title><source>Elsevier ScienceDirect Journals Complete</source><creator>He, Dongjie ; Yang, Yahui ; Wu, Peiwen ; Zhu, Siying ; Chang, Hao ; Zhang, Chao ; Shao, Qiuju ; Yu, Zongyan</creator><creatorcontrib>He, Dongjie ; Yang, Yahui ; Wu, Peiwen ; Zhu, Siying ; Chang, Hao ; Zhang, Chao ; Shao, Qiuju ; Yu, Zongyan</creatorcontrib><description>•In this population-based study that patients with MB, age-adjusted incidence rates remained relatively stable between 1975 and 2019.•Female incidence was stabilizing over time, while male incidence was increasing, with an APC of 0.35.This study evaluated independent prognostic factors associated with survival in patients with MB.•Patients with MB in the high-risk group may benefit from chemotherapy. Medulloblastoma (MB) is a primary brain malignancy. However, updated epidemiological data and long-term outcomes are lacking.The clinical and epidemiological datasets of patients with MB in the current study were obtained from the Surveillance, Epidemiology, and End Results (SEER) databases. Joinpoint regression models were used to assess the rate of changes in the incidence, prevalence, and treatment trends in patients with MB. Cox hazard and competition risk model analyses were used to assess overall survival (OS) and cancer-specific survival (CSS).The age-adjusted incidence of MB remained relatively stable at 0.15 per 100,000 individuals in 2019. The annual percentage change (APC) of females remained stable, whereas that of males increased over time. The 20-year limited-duration prevalence of patients with MB increased significantly from 0.00016 % in 1999 to 0.00203 % in 2018. Patients aged 5–19 years accounted for 46.7 % of all age groups, and the trend for the three treatments was increased. Average annual percentage change (AAPC) for the chemotherapy group was increased in patients aged 20 + years MB [AAPC = 2.66 (95 % CI 0.93–6.31)]. Multivariate analysis revealed that OS and CSS varied significantly according to age, year of diagnosis, histology, stage, surgery, and radiotherapy. Subgroup analysis showed that chemotherapy was associated with a favorable prognosis in high-risk groups.The incidence of MB remained relatively stable, and its prevalence increased significantly. This current population-based study further identified the prognostic factors in patients with MB. Moreover, the use of chemotherapy was associated with better survival in high-risk groups.</description><identifier>ISSN: 0967-5868</identifier><identifier>ISSN: 1532-2653</identifier><identifier>EISSN: 1532-2653</identifier><identifier>DOI: 10.1016/j.jocn.2024.06.011</identifier><identifier>PMID: 38901153</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Chemotherapy ; Incidence ; Medulloblastoma ; SEER ; Survival</subject><ispartof>Journal of clinical neuroscience, 2024-08, Vol.126, p.154-161</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-da49815a7eb2996a23f6490a8ab5d2f50cbe17d59827fc8cf83c684b538590cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jocn.2024.06.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38901153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Dongjie</creatorcontrib><creatorcontrib>Yang, Yahui</creatorcontrib><creatorcontrib>Wu, Peiwen</creatorcontrib><creatorcontrib>Zhu, Siying</creatorcontrib><creatorcontrib>Chang, Hao</creatorcontrib><creatorcontrib>Zhang, Chao</creatorcontrib><creatorcontrib>Shao, Qiuju</creatorcontrib><creatorcontrib>Yu, Zongyan</creatorcontrib><title>Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study</title><title>Journal of clinical neuroscience</title><addtitle>J Clin Neurosci</addtitle><description>•In this population-based study that patients with MB, age-adjusted incidence rates remained relatively stable between 1975 and 2019.•Female incidence was stabilizing over time, while male incidence was increasing, with an APC of 0.35.This study evaluated independent prognostic factors associated with survival in patients with MB.•Patients with MB in the high-risk group may benefit from chemotherapy. Medulloblastoma (MB) is a primary brain malignancy. However, updated epidemiological data and long-term outcomes are lacking.The clinical and epidemiological datasets of patients with MB in the current study were obtained from the Surveillance, Epidemiology, and End Results (SEER) databases. Joinpoint regression models were used to assess the rate of changes in the incidence, prevalence, and treatment trends in patients with MB. Cox hazard and competition risk model analyses were used to assess overall survival (OS) and cancer-specific survival (CSS).The age-adjusted incidence of MB remained relatively stable at 0.15 per 100,000 individuals in 2019. The annual percentage change (APC) of females remained stable, whereas that of males increased over time. The 20-year limited-duration prevalence of patients with MB increased significantly from 0.00016 % in 1999 to 0.00203 % in 2018. Patients aged 5–19 years accounted for 46.7 % of all age groups, and the trend for the three treatments was increased. Average annual percentage change (AAPC) for the chemotherapy group was increased in patients aged 20 + years MB [AAPC = 2.66 (95 % CI 0.93–6.31)]. Multivariate analysis revealed that OS and CSS varied significantly according to age, year of diagnosis, histology, stage, surgery, and radiotherapy. Subgroup analysis showed that chemotherapy was associated with a favorable prognosis in high-risk groups.The incidence of MB remained relatively stable, and its prevalence increased significantly. This current population-based study further identified the prognostic factors in patients with MB. Moreover, the use of chemotherapy was associated with better survival in high-risk groups.</description><subject>Chemotherapy</subject><subject>Incidence</subject><subject>Medulloblastoma</subject><subject>SEER</subject><subject>Survival</subject><issn>0967-5868</issn><issn>1532-2653</issn><issn>1532-2653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kctu3CAUhlHUKJmmfYEuKpbd2OViMK66iaL0IkXKpl0jDMctI2xcwBPNO_Shy2jSLrsC6XznF3w_Qm8oaSmh8v2-3Ue7tIywriWyJZReoB0VnDVMCv4C7cgg-0Yoqa7Ry5z3hJCh4-QKXXM1VFrwHfp9v3oHs48h_vDWBFwSLC5jszg8GVtiqveco_WmgMNPvvzEeUsHf6isX_Bqioel5PNkBreFEMdgcomz-YBvcSeaI5iE17huocJxaUaTa1SCkmJewRZ_AJzL5o6v0OVkQobXz-cN-v7p_tvdl-bh8fPXu9uHxjLel8aZblBUmB5GNgzSMD7JbiBGmVE4NgliR6C9E4Ni_WSVnRS3UnWj4EoMdchv0Ltz7prirw1y0bPPFkIwC8Qta056orginFaUnVFbH5sTTHpNfjbpqCnRpxb0Xp9a0KcWNJG6eq1Lb5_zt7Eq-bfyV3sFPp4BqL88eEg626rRgvOpCtEu-v_l_wE5SJws</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>He, Dongjie</creator><creator>Yang, Yahui</creator><creator>Wu, Peiwen</creator><creator>Zhu, Siying</creator><creator>Chang, Hao</creator><creator>Zhang, Chao</creator><creator>Shao, Qiuju</creator><creator>Yu, Zongyan</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240801</creationdate><title>Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study</title><author>He, Dongjie ; Yang, Yahui ; Wu, Peiwen ; Zhu, Siying ; Chang, Hao ; Zhang, Chao ; Shao, Qiuju ; Yu, Zongyan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-da49815a7eb2996a23f6490a8ab5d2f50cbe17d59827fc8cf83c684b538590cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chemotherapy</topic><topic>Incidence</topic><topic>Medulloblastoma</topic><topic>SEER</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Dongjie</creatorcontrib><creatorcontrib>Yang, Yahui</creatorcontrib><creatorcontrib>Wu, Peiwen</creatorcontrib><creatorcontrib>Zhu, Siying</creatorcontrib><creatorcontrib>Chang, Hao</creatorcontrib><creatorcontrib>Zhang, Chao</creatorcontrib><creatorcontrib>Shao, Qiuju</creatorcontrib><creatorcontrib>Yu, Zongyan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Dongjie</au><au>Yang, Yahui</au><au>Wu, Peiwen</au><au>Zhu, Siying</au><au>Chang, Hao</au><au>Zhang, Chao</au><au>Shao, Qiuju</au><au>Yu, Zongyan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study</atitle><jtitle>Journal of clinical neuroscience</jtitle><addtitle>J Clin Neurosci</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>126</volume><spage>154</spage><epage>161</epage><pages>154-161</pages><issn>0967-5868</issn><issn>1532-2653</issn><eissn>1532-2653</eissn><abstract>•In this population-based study that patients with MB, age-adjusted incidence rates remained relatively stable between 1975 and 2019.•Female incidence was stabilizing over time, while male incidence was increasing, with an APC of 0.35.This study evaluated independent prognostic factors associated with survival in patients with MB.•Patients with MB in the high-risk group may benefit from chemotherapy. Medulloblastoma (MB) is a primary brain malignancy. However, updated epidemiological data and long-term outcomes are lacking.The clinical and epidemiological datasets of patients with MB in the current study were obtained from the Surveillance, Epidemiology, and End Results (SEER) databases. Joinpoint regression models were used to assess the rate of changes in the incidence, prevalence, and treatment trends in patients with MB. Cox hazard and competition risk model analyses were used to assess overall survival (OS) and cancer-specific survival (CSS).The age-adjusted incidence of MB remained relatively stable at 0.15 per 100,000 individuals in 2019. The annual percentage change (APC) of females remained stable, whereas that of males increased over time. The 20-year limited-duration prevalence of patients with MB increased significantly from 0.00016 % in 1999 to 0.00203 % in 2018. Patients aged 5–19 years accounted for 46.7 % of all age groups, and the trend for the three treatments was increased. Average annual percentage change (AAPC) for the chemotherapy group was increased in patients aged 20 + years MB [AAPC = 2.66 (95 % CI 0.93–6.31)]. Multivariate analysis revealed that OS and CSS varied significantly according to age, year of diagnosis, histology, stage, surgery, and radiotherapy. Subgroup analysis showed that chemotherapy was associated with a favorable prognosis in high-risk groups.The incidence of MB remained relatively stable, and its prevalence increased significantly. This current population-based study further identified the prognostic factors in patients with MB. Moreover, the use of chemotherapy was associated with better survival in high-risk groups.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>38901153</pmid><doi>10.1016/j.jocn.2024.06.011</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0967-5868
ispartof Journal of clinical neuroscience, 2024-08, Vol.126, p.154-161
issn 0967-5868
1532-2653
1532-2653
language eng
recordid cdi_proquest_miscellaneous_3070838031
source Elsevier ScienceDirect Journals Complete
subjects Chemotherapy
Incidence
Medulloblastoma
SEER
Survival
title Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A14%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epidemiological%20trends%20and%20factors%20associated%20with%20survival%20in%20patients%20with%20medulloblastoma:%20A%2045-year%20population-based%20retrospective%20study&rft.jtitle=Journal%20of%20clinical%20neuroscience&rft.au=He,%20Dongjie&rft.date=2024-08-01&rft.volume=126&rft.spage=154&rft.epage=161&rft.pages=154-161&rft.issn=0967-5868&rft.eissn=1532-2653&rft_id=info:doi/10.1016/j.jocn.2024.06.011&rft_dat=%3Cproquest_cross%3E3070838031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070838031&rft_id=info:pmid/38901153&rft_els_id=S0967586824002492&rfr_iscdi=true